The expression of inhibitor of bruton’s tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis

Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy with a variable clinical outcome. Biomarkers of CLL progression are required for optimising prognosis and therapy. The Inhibitor of Bruton’s tyrosine kinase—isoform α (IBTKα) gene encodes a substrate receptor of Cullin 3-depend...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Albano, Francesco, Chiurazzi, Federico, Mimmi, Selena, Vecchio, Eleonora, Pastore, Arianna, Cimmino, Clementina, Frieri, Camilla, Iaccino, Enrico, Pisano, Antonio, Golino, Gaetanina, Fiume, Giuseppe, Mallardo, Massimo, Scala, Giuseppe, Quinto, Ileana
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849039/
https://ncbi.nlm.nih.gov/pubmed/29317636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0026-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados